PetVivo Holdings, Inc. (PETV): Entry into a Material Definitive Agreement
PetVivo Holdings, Inc. (PETV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT AND INVESTMENT LETTER PRIVATE OFFERING PETVIVO HOLDING, INC. (PETV) Common Stock and Warrant Offering - $0.80 Per Unit $2,500,000 March 2026 PetVivo Holdings, Inc., a Nevada corporation (“PetVivo”) is hereby offerin
How this was made
The 30-second read
Why it matters
The agreement details unit pricing ($0.80), warrant strike ($1.10), intended use of net proceeds (Spryng™ commercialization, product development/clinical trials, working capital), and an additional purchase option up to 1.5M units exercisable through June 15, 2026 (extendable 15 days).
Market read
Traders can update dilution/warrant overhang models immediately from the disclosed unit and warrant terms and the additional purchase option.
What to watch
No escrow and no minimum offering size are stated; actual closing size/timing could differ, changing dilution and near-term price pressure.
Background
The SEC 8-K reports entry into a material definitive agreement tied to a private offering of PetVivo common stock and warrants.
Ticker impact
PetVivo disclosed a private placement subscription agreement: units at $0.80 each with warrants exercisable at $1.10, plus an option for 1.5M more units.
Bias toward near-term downside/volatility on dilution expectations; upside possible only if investors view proceeds as sufficient for commercialization milestones.
The filing specifies unit pricing, warrant strike, intended use of proceeds, and a purchase option—core inputs traders use to model dilution and warrant overhang.
Market effects
Highlights ongoing financing needs typical of pre-commercial biotech/animal-health firms; warrant structures can increase overhang across similar issuers.
No specific regional impact indicated beyond US microcap financing dynamics.
Limited; this is company-specific capital-raise disclosure.
Counterpoint
If the commercialization/clinical plan is credible and investors expect rapid revenue traction, the raise could be viewed as de-risking the funding runway despite dilution.
Key entities
- issuerPetVivo Holdings, Inc.
Company entering the subscription agreement for a private placement of common stock and warrants.
- productSpryng™ with OsteoCushion™ Technology
Stated primary commercialization use of proceeds.
